← Leaderboards
Paul A. Johnston
University Of Pittsburgh At Pittsburgh
$5,329,293
Attributed
$6,661,971
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $986.5K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,661,971 · 6
By mechanism
R01$6,510,471 · 5
R21$151,500 · 1
Top collaborators
- Andrew P Hinck4 shared
- Thomas Edward Smithgall1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Jessie Nedrow$4,767,931
Others in their field
Top investigators on “Growth”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$233,131,631
- Albert Lazzarini · California Institute Of Technology$170,110,000
- David H Reitze · University Of Florida$170,110,000
- Garret A Fitzgerald · University Of Pennsylvania$153,184,124
- David Heimbrook · Leidos Biomedical Research, Inc.$143,966,408
- Carol Nesel · Westat$116,355,411
Research focus
GrowthResponseComplexTumorSmall MoleculeSignal TransductionLeadSignal PathwayFamilyCellsReceptorMalignant NeoplasmsPropertyAblationMalignant Neoplasm Of ProstateLigandsProstateCancer EtiologyBaseCessation Of LifePharmaceutical PreparationsKinase InhibitorCell ModelInhibitor/Antagonist
Grant awards (16)
Cell-Based HTS Campaign to Identify Negative Allosteric Modulators of the Leukemia-associated Tyrosine Kinase, BTKâ.$652,558
R01 · FY2025 · CA · contact PI
HTS for TGF-beta receptor assembly inhibitors with anti-tumor and anti-fibrosis activities$457,591
R01 · FY2022 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents$452,096
R01 · FY2022 · CA · contact PI
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents$512,558
R01 · FY2021 · CA · contact PI
HTS for TGF-beta receptor assembly inhibitors with anti-tumor and anti-fibrosis activities$473,901
R01 · FY2021 · CA
HTS for TGF-beta receptor assembly inhibitors with anti-tumor and anti-fibrosis activities$509,271
R01 · FY2020 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents$477,136
R01 · FY2020 · CA · contact PI
HTS for TGF-beta receptor assembly inhibitors with anti-tumor and anti-fibrosis activities$572,036
R01 · FY2019 · CA
qHTS of Patient Derived HCC Models to Identify Novel Probes/Therapeutic Agents$400,283
R01 · FY2019 · CA · contact PI
HCS to Identify Inhibitors and Disruptors of AR-TIF2 Interactions$338,926
R01 · FY2017 · CA · contact PI
HCS to Identify Inhibitors and Disruptors of AR-TIF2 Interactions$350,826
R01 · FY2016 · CA · contact PI
HCS to Identify Inhibitors and Disruptors of AR-TIF2 Interactions$389,435
R01 · FY2015 · CA · contact PI
Development of a Novel HCS Assay to Screen for Disruptors of AR-TIF2 Interactions$309,964
R01 · FY2014 · CA · contact PI
Development of a Novel HCS Assay to Screen for Disruptors of AR-TIF2 Interactions$297,452
R01 · FY2013 · CA · contact PI
Development of a Novel HCS Assay to Screen for Disruptors of AR-TIF2 Interactions$316,438
R01 · FY2012 · CA · contact PI
HCS Assay to Identify Disruptors of AR-TIF2 Protein-Protein Interactions$151,500
R21 · FY2011 · NS · contact PI